Log in
AGA

AGA 2022 guideline: pharmacological treatment of adult obesity

This guideline from the American Gastroenterological Association addresses the use of anti-obesity medications as an adjunct to lifestyle and behavioral interventions in adults with obesity. It emphasizes that pharmacotherapy should be considered for patients who have not achieved adequate weight loss or weight maintenance with lifestyle modification alone, and provides recommendations on specific agents available at the time.

AGA2022 editionSummary
Official guidelineAGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. AGA, 2022.
Read the official guideline · Checked for a newer edition on 2026-10-20
We do not reproduce the guideline text — this page is an independent summary.

Who it applies to

Adults with obesity (generally BMI 30 or higher, or BMI 27 or higher with weight-related comorbidities) being considered for medical weight management in addition to lifestyle therapy.

Key recommendations

  • Pharmacological treatment is recommended in addition to lifestyle intervention rather than lifestyle intervention alone for adults with obesity who have not responded sufficiently to lifestyle changes.
    strong
  • Semaglutide 2.4 mg weekly is recommended as an option, with evidence supporting meaningful weight loss compared with placebo when added to lifestyle intervention.
    strong
  • Liraglutide 3 mg daily is recommended as an option for weight management in addition to lifestyle intervention.
    strong
  • Phentermine-topiramate extended release is recommended as an option, having shown substantial weight loss benefit in trials.
    strong
  • Naltrexone-bupropion combination therapy is recommended as an option, though the magnitude of weight loss benefit is generally smaller than with some other agents.
    strong
  • Phentermine as monotherapy is suggested as an option for short-term use, reflecting its longstanding but more limited evidence base compared with newer agents.
    conditional
  • Orlistat is recommended as an option, with the panel noting its modest efficacy and gastrointestinal tolerability issues relative to newer agents.
    conditional
  • Choice among agents should be individualized based on efficacy, side effect profile, comorbidities, cost, and patient preference, since head-to-head comparative data are limited.

Practice points for students

  • Pharmacotherapy is intended to augment, not replace, lifestyle and behavioral interventions for obesity.
  • GLP-1 receptor agonists (semaglutide, liraglutide) generally produce greater weight loss than older agents like orlistat or phentermine alone.
  • Drug selection should weigh comorbidities (e.g., avoiding bupropion-naltrexone in uncontrolled hypertension or seizure disorder) and patient-specific factors.
  • The guideline includes both strong recommendations (for pharmacotherapy overall and for semaglutide, liraglutide, phentermine-topiramate, and naltrexone-bupropion) and conditional recommendations (for phentermine monotherapy and orlistat), reflecting differences in evidence certainty and magnitude of benefit.

Condition

Obesity

Other guidelines on this topic

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by AGA. It is not medical advice: always read the original guideline before applying it to patients.